Teologia come scienza, teologia come esperienza

La teologia come scienza nel Commento alle Sentenze. La discussione sulla trinità risale a conclusioni teologiche a partire dalla conoscenza sensibile.The theology as science in the Commentary to the Sentences . The discussion about trinity goes up to theological conclusions starting by the sensitive knowledge

The Monitoring System of the Belle II Vertex Detector

The Belle II VerteX Detector (VXD) is a 6 layers silicon tracker device that will cope with an unprecedented luminosity of 8 7 10 35 cm 12 2 s 12 1 achievable by the new SuperKEKB e + e 12 collider, at the KEK laboratory (Tsukuba, Japan). All environment parameters such as temperature, humidity and radiation levels, must be constantly monitored and under certain conditions action must be promptly taken, such as interlocking the power supply or delivering an abort signal to the SuperKEKB collider. In this contribution we describe the Belle II VXD monitoring system. We also present the first results of the temperature and humidity system commissioned in a Beam Test at DESY in April 2016 and the preliminary results of the radiation monitoring achieved with a prototype system during the first SuperKEKB commissioning phase at KEK in February-June 2016

The Software Framework of the Belle II Silicon Vertex Detector and its Development for the 2016 Test-Beam at DESY

The Silicon Vertex Detector of Belle II will be fundamental not only for the reconstruction of B meson vertices, but also for the reconstruction of neutral particles like K S , and the tracking of low- p t particles like slow pions associated with the decays of the abundant D 17 mesons. As a consequence great importance is given to the performance of the software that deals with the simulation and reconstruction of the SVD events. The Belle II experiment is the successor to Belle, one of the two experiments that first observed CP violation in the decay of B mesons. The SuperKEKB collider will deliver 40 times more luminosity than its predecessor KEKB, which requires major upgrades to the detector hardware. This also poses new challenges not only for the data collection and storage, but also for the software framework which is used to process and analyse the experimental data. In this article we present in detail the SVD software framework together with its development for the test of the Vertex Detector system, which took place at DESY in April 2016 using an electron beam

Performance studies of the Belle II Silicon Vertex Detector with data taken at the DESY test beam in April 2016

Belle II is a multipurpose detector currently under construction and it will be operated at the next generation B-factory SuberKEKB in Japan. The main Belle II devices, devoted to the vertex reconstruction, are the Silicon Vertex Detector (SVD) and the Pixel Detector (PXD). In April 2016 a sector of the Belle II SVD and PXD has been tested in a beam of high energetic electrons at the test beam facility at DESY Hamburg (Germany). We report here the results for the hit efficiency estimation and the measurement of the resolution for the Belle II silicon vertex detector. Hit efficiencies are measured to be on average above 99.5% and the measured resolution is within the expectations

The Belle II SVD detector

The Belle II VerteX Detector (VXD) is a 6 layers silicon tracker device that will cope with an unprecedented luminosity of 8 7 10 35 cm 12 2 s 12 1 achievable by the new SuperKEKB e + e 12 collider, at the KEK laboratory The Silicon Vertex Detector (SVD) is one of the main detectors in the Belle II experiment at KEK, Japan. In combination with a pixel detector, the SVD determines precise decay vertices and performs low-momentum track reconstruction. The SVD ladders are being developed at several institutes. For the development of the tracking algorithm as well as the performance estimation of the ladders, beam tests for the ladders were performed. We report an overview of the SVD development, its performance measured in the beam tests, and the prospect of its assembly and commissioning until installation

The atypical receptor CCRL2 (C-C Chemokine Receptor-Like 2) does not act as a decoy receptor in endothelial cells

C-C chemokine receptor-like 2 (CCRL2) is a non-signaling seven-transmembrane domain (7-TMD) receptor related to the atypical chemokine receptor (ACKR) family. ACKRs bind chemokines but do not activate G protein-dependent signaling or cell functions. ACKRs were shown to regulate immune functions in vivo by their ability to scavenge chemokines from the local environment. This study was performed to investigate whether CCRL2 shares two of the main characteristics of ACKRs, namely the ability to internalize and scavenge the ligands. Cell membrane analysis of CCRL2-transfected cells revealed a weak, constitutive, ligand-independent internalization, and recycling of CCRL2, with a kinetics that was slower than those observed with ACKR3, a prototypic ACKR, or other chemotactic signaling receptors [i.e., chemokine-like receptor 1 and C-X-C motif chemokine receptor 2]. Intracellularly, CCRL2 colocalized with early endosome antigen 1-positive and Rab5-positive vesicles and with recycling compartments mainly characterized by Rab11-positive vesicles. CCRL2-transfected cells and activated mouse blood endothelial cells, that endogenously express CCRL2, were used to investigate the scavenging ability of CCRL2. These experiments confirmed the ability of CCRL2 to bind chemerin, the only recognized ligand, but excluded the ability of CCRL2 to perform scavenging. Collectively, these results identify unique functional properties for this member of the non-signaling 7-TMD receptor family

Nutraceutical approach for the management of cardiovascular risk \u2013 a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

BACKGROUND: Probiotics incorporated into dairy products have been shown to reduce total (TC) and LDL cholesterolemia (LDL-C) in subjects with moderate hypercholesterolemia. More specifically, probiotics with high biliary salt hydrolase activity, e.g. Bifidobacterium longum BB536, may decrease TC and LDL-C by lowering intestinal cholesterol reabsorption and, combined with other nutraceuticals, may be useful to manage hypercholesterolemia in subjects with low cardiovascular (CV) risk. This study was conducted to evaluate the efficacy and safety of a nutraceutical combination containing Bifidobacterium longum BB536, red yeast rice (RYR) extract (10\u2009mg/day monacolin K), niacin, coenzyme Q10 (Lactoflorene Colesterolo\uae). The end-points were changes of lipid CV risk markers (LDL-C, TC, non-HDL-cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (ApoB), HDL-C, apolipoprotein AI (ApoAI), lipoprotein(a) (Lp(a), proprotein convertase subtilisin/kexin type 9 (PCSK9)), and of markers of cholesterol synthesis/absorption. METHODS: A 12-week randomized, parallel, double-blind, placebo-controlled study. Thirty-three subjects (18-70\u2009years) in primary CV prevention and low CV risk (SCORE: 0-1% in 24 and 2-4% in 9 subjects; LDL-C: 130-200\u2009mg/dL) were randomly allocated to either nutraceutical (N\u2009=\u200916) or placebo (N\u2009=\u200917). RESULTS: Twelve-week treatment with the nutraceutical combination, compared to placebo, significantly reduced TC (-\u200916.7%), LDL-C (-\u200925.7%), non-HDL-C (-\u200924%) (all p\u2009<\u20090.0001), apoB (-\u200917%, p\u2009=\u20090.003). TG, HDL-C, apoAI, Lp(a), PCSK9 were unchanged. Lathosterol:TC ratio was significantly reduced by the nutraceutical combination, while campesterol:TC ratio and sitosterol:TC ratio did not change, suggesting reduction of synthesis without increased absorption of cholesterol. No adverse effects and a 97% compliance were observed. CONCLUSIONS: A 12-week treatment with a nutraceutical combination containing the probiotic Bifidobacterium longum BB536 and RYR extract significantly improved the atherogenic lipid profile and was well tolerated by low CV risk subjects. TRIAL REGISTRATION: NCT02689934

Photoinduced Millisecond Switching Kinetics in the GFPMut2 E222Q Mutant

n/

Extra-peritoneal hysteroannessiectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details

Surgery allows the correct evaluation of the peritoneal dissemination of the epithelial ovarian cancer (EOC) and the removal of as much tumor as possible to maximize adjuvant chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery have been proposed as a reasonable alternative to primary complete cytoreductive surgery (CRS) in patients not fit for an initial extensive debulking surgery. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been offered as a promising therapeutic procedure to increase survival by treating the microscopic component of the neoplastic disease. Matherial and Method. 419 eligible patients with stage III-IV EOC were subjected to CRS, previous NACT in 343 patients, 20 of which with CRS combined with extraperitoneal hysterectomy (EH) + HIPEC. Purposes of our four years retrospective observational study are the revision of the surgical approaches to the EOC, a detailed report of the pelvic peritonectomy in association to hysteroannessiectomy (+/- consensual rectal resection) and the prospective review of the results. Conclusions. This study shows that EH + HIPEC is feasible. The detailed description of the technique here depicted could help to standardize this type of peritonectomy